Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer / Iaffaioli, R. V.; Tortoriello, A.; Facchini, G.; Santangelo, Michele; De Sena, G.; Gesue, G.; Bucci, Luigi; Scaramellino, G.; Anastasio, E.; Finizio, A.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 72:5(1995), pp. 1256-1258.
A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
SANTANGELO, MICHELE;BUCCI, LUIGI;
1995
Abstract
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
